Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Provigil Revamped Marketing Campaign To Launch After FDA Cites Promotions

Executive Summary

Cephalon plans to proceed with a new marketing program for Provigil (modafinil) in February after receiving a letter from FDA objecting to many of its current promotional materials for the narcolepsy drug

You may also be interested in...



Cephalon Marketing Under Investigation By Philadelphia U.S. Attorney

The Philadelphia U.S. Attorney's investigation into Cephalon's marketing practices covers the entire commercial life of Provigil

Cephalon Marketing Under Investigation By Philadelphia U.S. Attorney

The Philadelphia U.S. Attorney's investigation into Cephalon's marketing practices covers the entire commercial life of Provigil

FDA Drug Safety Upgrades Coming; Medicare Bill Could Help Win Funding

The Medicare prescription drug coverage legislation should help FDA make the case for additional funding for post-marketing surveillance, according to Center for Drug Evaluation & Research Acting Director Steven Galson, MD

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS039194

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel